Telzap, tablets 80 mg 30 pcs

Pharmacodynamics

Telmisartan is a specific angiotensin II receptor antagonist (AT₁ type), effective when taken orally. It has a very high affinity for the AT₁ receptor subtype, through which angiotensin II action is realized. Telmisartan displaces angiotensin II from binding to the receptor without having an agonist effect against this receptor; it binds only to the AT₁ receptor subtype of angiotensin II. Binding is stable.

Telmisartan has no affinity for other receptors, including AT₂ receptors and other less studied angiotensin receptors. The functional significance of these receptors, as well as the effect of their possible overstimulation by angiotensin II, the concentration of which increases with telmisartan administration, has not been studied. Telmisartan reduces plasma aldosterone concentration, does not reduce renin activity and does not block ion channels. Telmisartan does not inhibit ACE (kininase II), which also catalyzes the destruction of bradykinin. This avoids side effects associated with the action of bradykinin (e.g., dry cough).

Essential hypertension

Telmisartan at a dose of 80 mg completely blocks the hypertensive effects of angiotensin II. The onset of antihypertensive action is noted within 3 h after the first dose of telmisartan. The action of the drug persists for 24 h and remains clinically significant up to 48 h. Significant antihypertensive effect usually develops 4-8 weeks after regular use.

In patients with arterial hypertension, telmisartan reduces systolic and diastolic BP without affecting HR.

In case of abrupt discontinuation of telmisartan, BP gradually returns to baseline within a few days without development of “withdrawal” syndrome.

As the results of comparative clinical studies have shown, the antihypertensive effect of telmisartan is comparable to other classes of drugs (amlodipine, atenololol, enalapril, hydrochlorothiazide and lisinopril).

The incidence of dry cough was significantly lower with telmisartan compared with ACE inhibitors.

The prevention of cardiovascular disease

. In patients aged 55 years or older with CHD, stroke, transient ischemic attack, peripheral artery disease, or with complications of type 2 diabetes (e.g., retinopathy, left ventricular hypertrophy, macro- or microalbuminuria) in a history of cardiovascular events at risk, telmisartan had similar effects to ramipril in reducing the combined end point cardiovascular mortality from nonfatal myocardial infarction, nonfatal stroke, and hospitalization for chronic heart failure.

Telmisartan was as effective as ramipril in reducing the incidence of secondary points: cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke.

Dry cough and angioedema were less commonly described with telmisartan compared with ramipril, and arterial hypotension was more common with telmisartan.

Patients in children and adolescents

The safety and efficacy of telmisartan in children and adolescents under 18 years of age have not been established.

Pharmacokinetics

Indications

– essential hypertension;

– reduction of mortality and incidence of cardiovascular disease in adult patients with cardiovascular disease of atherothrombotic genesis (CHD, stroke or peripheral artery disease in the history) and with type 2 diabetes with target organ damage.

.

Active ingredient

Telmisartan

Composition

1 tablet – telmisartan 80 mg

Interaction

Dual RAAS blockade

The concomitant use of telmisartan with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (FFR less than 60 ml/min/1.73 m² body surface area) and is not recommended in other patients.

The concomitant use of telmisartan and ACE inhibitors is contraindicated in patients with diabetic nephropathy.

The data from clinical studies have shown that dual RAAS blockade due to combined use of ACE inhibitors, angiotensin II receptor antagonists or aliskiren is associated with an increased incidence of adverse events such as arterial hypotension, hyperkalemia and impaired renal function (including acute renal failure) compared to use of a single drug acting on RAAS alone.

Hyperkalemia

The risk of hyperkalemia may increase when co-administered with other medications that can cause hyperkalemia (potassium-containing supplements and salt substitutes containing potassium, potassium-saving diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), NSAIDs (including selective COX-2 inhibitors), heparin, immunosuppressants (cyclosporine or tacrolimus) and trimethoprim). If necessary, against the background of documented hypokalemia, co-administration of drugs should be performed with caution and plasma potassium content should be regularly monitored.

Digoxin

When telmisartan was coadministered with digoxin, there was an average increase in plasma C_max of digoxin by 49% and C_min by 20%. Plasma digoxin concentrations should be carefully monitored at initiation of treatment, dose selection, and discontinuation of telmisartan treatment to maintain them within the therapeutic range.

Kalium-saving diuretics or potassium-containing supplements

Angiotensin II receptor antagonists, such as telmisartan, reduce diuretic-induced potassium loss. Potassium-saving diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium-containing supplements, or salt substitutes may result in a significant increase in plasma potassium. If concomitant use is indicated because there is documented hypokalemia, they should be used with caution and with regular monitoring of plasma potassium.

Lithium preparations

The co-administration of lithium preparations with ACE inhibitors and angiotensin II receptor antagonists, including telmisartan, has resulted in reversible increases in plasma lithium concentration and its toxic effects. If it is necessary to use this combination of drugs, it is recommended to carefully monitor plasma lithium concentrations.

NSAIDs

NSAIDs (i.e., acetylsalicylic acid in doses used for anti-inflammatory treatment, COX-2 inhibitors and non-selective NSAIDs) may impair the antihypertensive effect of angiotensin II receptor antagonists. In some patients with impaired renal function (e.g., patients with dehydration, elderly patients with impaired renal function), coadministration of angiotensin II receptor antagonists and COX-2 inhibitors may lead to further deterioration of renal function, including development of acute renal failure, which is usually reversible. Therefore, the combined use of drugs should be used with caution, especially in elderly patients. Adequate fluid intake should be ensured, and renal function parameters should be monitored at the beginning of coadministration and periodically thereafter.

Diuretics (thiazide or “loop”)

Prior treatment with high-dose diuretics such as furosemide (“loop” diuretic) and hydrochlorothiazide (thiazide diuretic) may lead to hypovolemia and risk of arterial hypotension at the start of telmisartan treatment.

Other hypotensive drugs

The effect of telmisartan may be enhanced when other hypotensive drugs are used together.

Based on the pharmacological properties of baclofen and amifostine, it can be assumed that they will enhance the therapeutic effect of all hypotensive drugs, including telmisartan. In addition, orthostatic hypotension may be increased with ethanol, barbiturates, narcotics or antidepressants.

Corticosteroids (for systemic use)

Corticosteroids impair the effects of telmisartan.

Directions for use

The drug is taken orally, once daily, regardless of meals; tablets should be washed down with fluids.

Hypertension

The initial recommended dose of Telzap ^® is 40 mg (1 tablet) once daily. In some patients, a dose of 20 mg/day may be effective. A dose of 20 mg can be obtained by dividing the 40 mg tablet in half at a risk. In cases where therapeutic effect is not achieved, the recommended dose of Telzap^® may be increased to a maximum of 80 mg once daily.

As an alternative, Telzap^® may be taken in combination with thiazide diuretics such as hydrochlorothiazide, which had an additional antihypertensive effect when used together. When deciding whether to increase the dose, it should be taken into account that the maximum antihypertensive effect is usually achieved within 4-8 weeks after the start of treatment.

Decrease in cardiovascular mortality and incidence

The recommended dose of Telzap® is 80 mg once daily. During the initial period of treatment, monitoring of BP is recommended; correction of hypotensive therapy may be necessary.

The experience with telmisartan in patients with severe renal impairment or patients on hemodialysis is limited. A lower starting dose of 20 mg/day is recommended in these patients. No dose adjustment is required for patients with mild to moderate renal impairment.

The concomitant use of Telzap^® with aliskiren is contraindicated in patients with renal impairment (FFR less than 60 ml/min/1.73 m² body surface area).

The concomitant use of Telzap^® with ACE inhibitors is contraindicated in patients with diabetic nephropathy.

Patients with mild to moderate hepatic impairment (Child-Pugh Class A and B) should use the drug with caution and the dose should not exceed 40 mg once daily. Telzap® is contraindicated in patients with severe hepatic failure (Child-Pugh class C).

Dose adjustment is not required in elderly patients.

The use of Telzap® in children and adolescents under 18 years of age is contraindicated because of lack of data about safety and effectiveness.

Special Instructions

Hepatic impairment

The use of Telzap^® is contraindicated in patients with cholestasis, biliary obstruction or severe hepatic impairment (Child-Pugh class C) because telmisartan is mainly excreted with bile. It is assumed that hepatic clearance of telmisartan is reduced in such patients. Telzap^® should be used with caution in patients with mild to moderate hepatic impairment (Child-Pugh grades A and B).

Renovascular hypertension

Patients with bilateral renal artery stenosis or artery stenosis of the only functioning kidney increase the risk of severe arterial hypotension and renal failure when treated with drugs acting on the RAAS.

Kidney dysfunction and renal transplantation

In patients with impaired renal function, periodic monitoring of plasma potassium and creatinine is recommended during use of Telzap^®. There is no clinical experience with Telzap^® in patients who have recently undergone a kidney transplant.

Symptomatic arterial hypotension, especially after the first administration of Telzap^® may occur in patients with decreased RBC and/or plasma sodium content on the background of previous treatment with diuretics, restriction of table salt intake, diarrhea or vomiting. Such conditions (fluid and/or sodium deficiency) should be eliminated before starting the drug Telzap®.

Double RAS blockade

The concomitant use of telmisartan with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR less than 60 ml/min/1.73 m² body surface area).

The concomitant use of telmisartan and ACE inhibitors is contraindicated in patients with diabetic nephropathy.

As a result of RAAS inhibition arterial hypotension, syncope, hyperkalemia and renal dysfunction (including acute renal failure) have been reported in prone patients, especially when multiple drugs also acting on this system are used together. Therefore, dual RAAS blockade (e.g. with telmisartan with other RAAS antagonists) is not recommended.

In cases where vascular tone and renal function are predominantly dependent on RAAS activity (e.g., in patients with chronic heart failure or renal disease including in patients with renal artery stenosis or stenosis of the artery of the only kidney), the administration of drugs affecting this system may be accompanied by the development of acute arterial hypotension, hyperazotemia, oliguria, and in rare cases, acute renal failure.

Primary hyperaldosteronism

In patients with primary hyperaldosteronism, treatment with hypotensive drugs that work by inhibiting the RAAS is usually ineffective. Due to this reason the use of Telzap® is not recommended.

Aortic and mitral valve stenosis, hypertrophic obstructive cardiomyopathy

. As with other vasodilators, patients with aortic or mitral stenosis and hypertrophic obstructive cardiomyopathy should exercise extreme caution when using Telzap^®.

Patients with diabetes mellitus who have received insulin or oral hypoglycemic agents

Hypoglycemia may occur in these patients during treatment with Telzap^®. Glycemic control should be strengthened, since adjustment of the dose of insulin or hypoglycemic agent may be necessary.

Hyperkalemia

The use of drugs acting on the RAAS may cause hyperkalemia. In elderly patients, patients with renal insufficiency or diabetes mellitus, patients taking medications that increase plasma potassium content, and/or patients with comorbidities, hyperkalemia can lead to death.

When deciding on concomitant use of drugs acting on the RAAS, the risk-benefit ratio should be assessed. The main risk factors for hyperkalemia that should be considered are:

– diabetes mellitus, renal failure, age (patients older than 70 years);

– combination with one or more RAAS-acting drugs and/or potassium-containing supplements. Drugs or therapeutic classes of drugs that may cause hyperkalemia are potassium-containing salt substitutes, potassium-saving diuretics, ACE inhibitors, angiotensin II receptor antagonists, NSAIDs (including selective COX-2 inhibitors), heparin, immunosuppressants (cyclosporine or tacrolimus), and trimethoprim;

– intercurrent diseases, especially dehydration, acute heart failure, metabolic acidosis, renal dysfunction, cytolysis syndrome (e.g., acute limb ischemia, rhabdomyolysis, extensive trauma).

Patients at risk are advised to carefully monitor plasma potassium levels.

Sorbitol

The drug Telzap^® contains sorbitol (E420). Patients with rare hereditary fructose intolerance should not take the drug.

Ethnic differences

As noted for ACE inhibitors, telmisartan and other angiotensin II receptor antagonists appear to reduce BP less effectively in black patients than in other races, possibly due to a greater predisposition to reduced renin activity in these patient populations.

Other

As with other hypotensive agents, excessive BP reduction in patients with ischemic cardiomyopathy or CHD can lead to myocardial infarction or stroke.

Impact on driving and operating machinery

There have been no special clinical studies to study the effect of the drug on driving and operating machinery. Caution should be used when driving vehicles and operating mechanisms with increased concentration, because dizziness and somnolence may occur rarely during the use of Telzap®.

Contraindications

– obstructive biliary tract disease;

– severe liver function impairment (Child-Pugh class C);

– co-administration with aliskiren in patients with diabetes or severe renal impairment (GFR less than 60 ml/min/1.73 m² body surface area);

– concomitant use with ACE inhibitors in patients with diabetic nephropathy;

– hereditary fructose intolerance (due to sorbitol in the drug);

– pregnancy;

– period of breastfeeding;

– age under 18 years (effectiveness and safety have not been established);

– hypersensitivity to the active substance or any excipients of the drug.

With caution, the drug should be administered in bilateral renal artery stenosis or artery stenosis of the only functioning kidney; renal impairment; mild to moderate hepatic impairment; decreased BAC with prior diuretic use, restriction of table salt intake, diarrhea or vomiting; hyponatremia; hyperkalemia; conditions after kidney transplantation (no experience of use); severe chronic heart failure; aortic and mitral valve stenosis; hypertrophic obstructive cardiomyopathy; primary hyperaldosteronism (effectiveness and safety not established); patients of non-gracial race.

Side effects

According to WHO, adverse effects are classified according to their frequency of occurrence as follows: very common (≥1/10), common (≥1/100 to < 1/10), infrequent (≥1/1000 to < 1/100), rare (≥1/10 000 to < 1/1000), very rare (< 1/10 000); frequency unknown – it was not possible to determine the incidence based on available data.

Within each group, according to frequency of occurrence, adverse reactions are presented in descending order of severity.

Infectious and parasitic diseases: infrequent – urinary tract infections, including cystitis, upper respiratory tract infections, including pharyngitis and sinusitis; rarely – sepsis, including lethal outcome.

With the hematopoietic system: infrequent anemia; rarely – eosinophilia, thrombocytopenia.

The immune system: rarely – anaphylactic reaction and hypersensitivity.

Metabolism: infrequent hyperkalemia; rarely – hypoglycemia (in patients with diabetes).

Mental disorders: infrequent – insomnia, depression; rarely – anxiety.

Nervous system disorders: infrequent – fainting; rarely – somnolence.

An organ of vision: rare – visual disturbances.

Hearing organ and labyrinth disorders: infrequent – vertigo.

Cardiovascular system: infrequent – bradycardia, marked BP decrease, orthostatic hypotension; rarely – tachycardia.

Respiratory system: infrequent dyspnea, cough; very rare – interstitial lung disease.

Gastrointestinal disorders: infrequent – abdominal pain, diarrhea, dyspepsia, flatulence, vomiting; rare – dry mouth, discomfort in the stomach, violation of taste.

Liver and biliary tract disorders: rare – liver dysfunction/liver damage.

Skin and subcutaneous tissue disorders: infrequent – skin itching, hyperhidrosis, rash; rarely – angioedema (also fatal), eczema, erythema, urticaria, drug rash, toxic skin rash.

Muscular system disorders: infrequent – ischialgia, muscle cramps, myalgia; rarely – arthralgia, pain in the extremities, tendinitis-like syndrome.

Urinary system disorders: infrequent – renal dysfunction, including acute renal failure.

Laboratory and instrumental disorders: infrequent increase of creatinine concentration in plasma, rare decrease of hemoglobin, increase of uric acid in plasma, increase of liver enzymes activity and CPK.

Others: infrequent – chest pain, asthenia; rarely – flu-like syndrome.

Overdose

Symptoms: the most pronounced manifestations of overdose were marked BP decrease and tachycardia; bradycardia, dizziness, increased serum creatinine concentration and acute renal failure have also been reported.

Treatment: Patients should be closely monitored and symptomatic as well as supportive treatment should be given. The approach to treatment depends on the time since the drug administration and the severity of symptoms. Recommended interventions include inducing vomiting and/or gastric lavage, and administration of activated charcoal is advisable. Plasma electrolytes and creatinine should be monitored regularly. In case of excessive BP decrease, the patient should take a horizontal position with elevated legs, and the CBC and electrolyte deficit should be quickly replenished. Telmisartan is not excreted by hemodialysis.

Pregnancy use

There is currently no reliable information on the safety of telmisartan in pregnant women. Reproductive toxicity of the drug has been detected in animal studies.

Similarities

Mycardis, Telsartan, Telzap, Telmista, Telpres, Telmisartan